Literature DB >> 34251530

Brain Endothelial Cells: Metabolic Flux and Energy Metabolism.

Cade J McDonald1, Zachery J Blankenheim1, Lester R Drewes2.   

Abstract

The neurovascular unit (NVU) consists of multiple cell types including brain endothelial cells, pericytes, astrocytes, and neurons that function collectively to maintain homeostasis within the CNS microenvironment. As the principal barrier-forming component of the NVU, the endothelial cells perform an array of complex functions that require substantial energy resources. The principal metabolic pathways for producing ATP are glycolysis and mitochondrial oxidative phosphorylation. While previous studies have demonstrated that glycolysis is a primary pathway for most endothelial cells, details about the energy producing pathways of brain endothelial cells are not fully characterized. The contributions of glycolysis and mitochondrial respiration to energy metabolism are quantifiable using metabolic flux analysis that measures cellular oxygen consumption and acidification (proton production) in a closed microtiter plate format. ATP production rates are then calculated. The bioenergetics of the human brain microvascular endothelial cell line, hCMEC/D3, indicate that these cells exhibit relatively elevated rates of glycolytic flux and glycolytic ATP production, thus confirming their glycolytic nature even in the presence of abundant oxygen. Furthermore, energy producing pathways involving mitochondrial respiration are relatively low, although contributing significantly to total ATP production. Interestingly, the bioenergetics of the hCMEC/D3 cells are relatively similar to those of human primary brain microvascular endothelial cells (hBVECs). These findings allow a quantitative understanding of the bioenergetics of brain endothelial cells in a cultured and proliferative state and also provide a platform for comparative studies of disease states and conditions involving exposures to drugs or metabolic disruptors.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Bioenergetics; Endothelial cell; Glycolysis; Neurovascular unit; Respiration

Mesh:

Substances:

Year:  2022        PMID: 34251530     DOI: 10.1007/164_2021_494

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  58 in total

Review 1.  Endothelial cell heterogeneity.

Authors:  William C Aird
Journal:  Cold Spring Harb Perspect Med       Date:  2012-01       Impact factor: 6.915

Review 2.  Structure and function of the blood-brain barrier.

Authors:  N Joan Abbott; Adjanie A K Patabendige; Diana E M Dolman; Siti R Yusof; David J Begley
Journal:  Neurobiol Dis       Date:  2009-08-05       Impact factor: 5.996

Review 3.  Drug delivery to the brain in Alzheimer's disease: consideration of the blood-brain barrier.

Authors:  William A Banks
Journal:  Adv Drug Deliv Rev       Date:  2011-12-17       Impact factor: 15.470

Review 4.  Tricarboxylic acid cycle dysfunction as a cause of human diseases and tumor formation.

Authors:  Jean-Jacques Brière; Judith Favier; Anne-Paule Gimenez-Roqueplo; Pierre Rustin
Journal:  Am J Physiol Cell Physiol       Date:  2006-06-07       Impact factor: 4.249

Review 5.  Cancer cell metabolism and mitochondria: Nutrient plasticity for TCA cycle fueling.

Authors:  Cyril Corbet; Olivier Feron
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-01-18       Impact factor: 10.680

Review 6.  The blood-brain barrier: an overview: structure, regulation, and clinical implications.

Authors:  Praveen Ballabh; Alex Braun; Maiken Nedergaard
Journal:  Neurobiol Dis       Date:  2004-06       Impact factor: 5.996

7.  Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects.

Authors:  Cyril Corbet; Estelle Bastien; Nihed Draoui; Bastien Doix; Lionel Mignion; Bénédicte F Jordan; Arnaud Marchand; Jean-Christophe Vanherck; Patrick Chaltin; Olivier Schakman; Holger M Becker; Olivier Riant; Olivier Feron
Journal:  Nat Commun       Date:  2018-03-23       Impact factor: 14.919

8.  Dual Inhibition of the Lactate Transporters MCT1 and MCT4 Is Synthetic Lethal with Metformin due to NAD+ Depletion in Cancer Cells.

Authors:  Don Benjamin; Dimitri Robay; Sravanth K Hindupur; Jens Pohlmann; Marco Colombi; Mahmoud Y El-Shemerly; Sauveur-Michel Maira; Christoph Moroni; Heidi A Lane; Michael N Hall
Journal:  Cell Rep       Date:  2018-12-11       Impact factor: 9.423

9.  MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.

Authors:  Mounia Beloueche-Babari; Slawomir Wantuch; Teresa Casals Galobart; Markella Koniordou; Harold G Parkes; Vaitha Arunan; Yuen-Li Chung; Thomas R Eykyn; Paul D Smith; Martin O Leach
Journal:  Cancer Res       Date:  2017-09-18       Impact factor: 12.701

10.  Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Authors:  Nicola J Curtis; Lorraine Mooney; Lorna Hopcroft; Filippos Michopoulos; Nichola Whalley; Haihong Zhong; Clare Murray; Armelle Logie; Mitchell Revill; Kate F Byth; Amanda D Benjamin; Mike A Firth; Stephen Green; Paul D Smith; Susan E Critchlow
Journal:  Oncotarget       Date:  2017-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.